Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer

BACKGROUND: We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor–positive metastatic breast cancer who had been randomly assigned to receive the aromatase inhibitor anastrozole plus the selective estr...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:N Engl J Med
Prif Awduron: Mehta, Rita S., Barlow, William E., Albain, Kathy S., Vandenberg, Ted A., Dakhil, Shaker R., Tirumali, Nagendra R., Lew, Danika L., Hayes, Daniel F., Gralow, Julie R., Linden, Hannah M., Livingston, Robert B., Hortobagyi, Gabriel N.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6885383/
https://ncbi.nlm.nih.gov/pubmed/30917258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1811714
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg